A Phase 1 interventional study of Flortaucipir F18 and Brain PET scan in Alzheimer Disease and Mild Cognitive Impairment, sponsored by Avid Radiopharmaceuticals. Completed. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-25.
Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.
Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 10th largest by enrollment, is one of 4 that started in 2014, is one of 10 in phase 1, and was the 20th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:
Eli Radiopharma · Sites in China
Ages 50–85 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 50+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 21–80
By country, each count listing its studies:
flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 7 · Phase 3 4 · Phase 4 1
First in 2013; this study’s year is marked. 4 started in 2014.
This study's enrollment of 89 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 70 across the 22 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
This study is registered under Avid Radiopharmaceuticals, one of the names counted as Eli Lilly and Company. Under that name alone:
Avid Radiopharmaceuticals is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
99 studies in Alzheimer Disease by Eli Lilly and Company: 13 open now, 19 under way, 8 of them phase 3. Of 79 finished, 61 (77%) have results posted.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 50th largest by enrollment of the 95 interventional ones that give a count, is one of 8 that started in 2014, is one of 34 in phase 1, and was the 76th registered.
Eli Lilly and Company’s Alzheimer Disease studies by the year they started, since 2002.
2 of the studies testing flortaucipir in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07580703Eli RadiopharmaA Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy | 2026-12-31 |
| NCT02740634Mayo ClinicMolecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing flortaucipir in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 99 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.
The Australian Imaging Biomarkers and Lifestyle Study (AIBL) is a multicenter multidisciplinary study of Alzheimer's disease and aging funded by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) Flagship Initiative, involving research centers in both Victoria and Western Australia. The goal of the A08 protocol was to further investigate the positron emission tomography (PET) imaging results with flortaucipir in patients across the AD spectrum from individuals with subjective memory complaints (SMC) to those with dementia, based on recruitment into the parent AIBL study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alzheimer's disease subjects receiving a flortaucipir PET scan at baseline and 12 months
Drug: Flortaucipir F18 · Procedure: Brain PET scan
Mild cognitive impairment subjects receiving a flortaucipir PET scan at baseline and 12 months
Drug: Flortaucipir F18 · Procedure: Brain PET scan
Subjective memory complainers receiving a flortaucipir PET scan at baseline and 12 months
Drug: Flortaucipir F18 · Procedure: Brain PET scan
Cognitively normal subjects receiving a flortaucipir PET scan at baseline and 12 months
Drug: Flortaucipir F18 · Procedure: Brain PET scan
IV injection, 240 megabecquerel (MBq) (6.5 mCi)
Also known as: 18F-AV-1451, [F-18]T807, LY3191748, Tauvid
positron emission tomography (PET) scan of the brain
Flortaucipir PET Imaging (Quantitative)
Flortaucipir PET cortical weighted average standardized uptake value ratio (SUVr). For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
Time frame: baseline scan
Number of Participants With Advanced AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status
Scans were visually read independently by two expert readers at the sponsor, blinded to any clinical information. Subject scans were categorized as follows: Advanced AD Scan Pattern (τAD++), Moderate AD Scan Pattern (τAD+), Not AD Scan Pattern (τAD-). For this analysis, subjects with Advanced (τAD++) scans were analyzed vs. the combined Moderate and Not AD pattern groups (τAD+/τAD-). Amyloid status was obtained by florbetapir or carbon-11-labeled Pittsburgh compound B (\[C-11\] PiB) PET results available from the parent AIBL study.
Time frame: baseline scan
Number of Participants With AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status
Scans were visually read independently by two expert readers at the sponsor, blinded to any clinical information. Subject scans were categorized as follows: Advanced AD Scan Pattern (τAD++), Moderate AD Scan Pattern (τAD+), Not AD Scan Pattern (τAD-). For this analysis, subjects with AD Pattern scans (Advanced \[τAD++\] and Moderate \[τAD+\] Scan Pattern) were combined vs. the Not AD pattern group (τAD-). Amyloid status was obtained by florbetapir or carbon-11-labeled Pittsburgh compound B (\[C-11\] PiB) PET results available from the parent AIBL study.
Time frame: baseline scan
Enrollment occurred between Oct 2014 and Feb 2018 from the Australian Imaging, Biomarker \& Lifestyle Flagship Study of Ageing (AIBL)
| Milestone | Alzheimer's Disease (AD) | Mild Cognitive Impairment (MCI) | Subjective Memory Complainers (SMC) | Cognitively Normal (CN) |
|---|---|---|---|---|
| Started | 6 | 11 | 47 | 25 |
| Baseline flortacuipir pet scan | 5 | 11 | 45 | 25 |
| Completed | 4 | 10 | 41 | 21 |
| Not completed | 2 | 1 | 6 | 4 |
| Withdrew: Withdrawal by subject | 0 | 1 | 3 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
Flortaucipir PET cortical weighted average standardized uptake value ratio (SUVr). For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
| standardized uptake value ratio (SUVr) | Alzheimer's Disease (AD) | Mild Cognitive Impairment (MCI) | Objectively Impaired | Subjective Memory Complainers (SMC) | Cognitively Normal (CN) | Non-objectively Compared |
|---|---|---|---|---|---|---|
| Flortaucipir PET Imaging (Quantitative) | 1.31 ± 0.059 | 1.13 ± 0.033 | 1.15 ± 0.031 | 1.08 ± 0.016 | 1.04 ± 0.028 | 1.07 ± 0.015 |
Scans were visually read independently by two expert readers at the sponsor, blinded to any clinical information. Subject scans were categorized as follows: Advanced AD Scan Pattern (τAD++), Moderate AD Scan Pattern (τAD+), Not AD Scan Pattern (τAD-). For this analysis, subjects with Advanced (τAD++) scans were analyzed vs. the combined Moderate and Not AD pattern groups (τAD+/τAD-). Amyloid status was obtained by florbetapir or carbon-11-labeled Pittsburgh compound B (\[C-11\] PiB) PET results available from the parent AIBL study.
| Participants | Alzheimer's Disease (AD) | Mild Cognitive Impairment (MCI) | Subjective Memory Complainers (SMC) | Cognitively Normal (CN) |
|---|---|---|---|---|
| Amyloid Positive — Advanced AD Scan Pattern (τAD++) | 2 | 3 | 9 | 0 |
| Amyloid Positive — Not Advanced AD Pattern | 2 | 2 | 11 | 4 |
| Amyloid Negative — Advanced AD Scan Pattern (τAD++) | 1 | 0 | 3 | 1 |
| Amyloid Negative — Not Advanced AD Pattern | 0 | 6 | 22 | 20 |
Scans were visually read independently by two expert readers at the sponsor, blinded to any clinical information. Subject scans were categorized as follows: Advanced AD Scan Pattern (τAD++), Moderate AD Scan Pattern (τAD+), Not AD Scan Pattern (τAD-). For this analysis, subjects with AD Pattern scans (Advanced \[τAD++\] and Moderate \[τAD+\] Scan Pattern) were combined vs. the Not AD pattern group (τAD-). Amyloid status was obtained by florbetapir or carbon-11-labeled Pittsburgh compound B (\[C-11\] PiB) PET results available from the parent AIBL study.
| Participants | Alzheimer's Disease (AD) | Mild Cognitive Impairment (MCI) | Subjective Memory Complainers (SMC) | Cognitively Normal (CN) |
|---|---|---|---|---|
| Amyloid Positive — AD Pattern Scan (Advanced or Moderate) | 2 | 4 | 11 | 0 |
| Amyloid Positive — Not AD Pattern Scan | 2 | 1 | 9 | 4 |
| Amyloid Negative — AD Pattern Scan (Advanced or Moderate) | 1 | 0 | 6 | 1 |
| Amyloid Negative — Not AD Pattern Scan | 0 | 6 | 19 | 20 |
Collected over End of study for AE reporting was 48 hours after flortaucipir administration at each imaging visit.. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alzheimer's Disease (AD) | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Mild Cognitive Impairment (MCI) | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| Subjective Memory Complainers (SMC) | 0/45 (0%) | 0/45 (0%) | 1/45 (2.2%) |
| Cognitively Normal (CN) | 0/25 (0%) | 0/25 (0%) | 1/25 (4%) |
| Event | Alzheimer's Disease (AD) | Mild Cognitive Impairment (MCI) | Subjective Memory Complainers (SMC) | Cognitively Normal (CN) |
|---|---|---|---|---|
| dermatitis contactSkin and subcutaneous tissue disorders | 0/5 | 0/11 | 0/45 | 1/25 |
| headacheNervous system disorders | 0/5 | 0/11 | 1/45 | 0/25 |
| Age, Continuous(years) | Alzheimer's Disease (AD) | Mild Cognitive Impairment (MCI) | Subjective Memory Complainers (SMC) | Cognitively Normal (CN) | Total |
|---|---|---|---|---|---|
| Mean | 76.2 ± 6.53 | 74.3 ± 5.82 | 77 ± 7.43 | 72.9 ± 4.67 | 75.4 ± 6.64 |
| Sex: Female, Male(Participants) | Alzheimer's Disease (AD) | Mild Cognitive Impairment (MCI) | Subjective Memory Complainers (SMC) | Cognitively Normal (CN) | Total |
|---|---|---|---|---|---|
| Female | 2 | 4 | 26 | 13 | 45 |
| Male | 3 | 7 | 19 | 12 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Alzheimer's Disease (AD) | Mild Cognitive Impairment (MCI) | Subjective Memory Complainers (SMC) | Cognitively Normal (CN) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 11 | 45 | 25 | 86 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Alzheimer's Disease (AD) | Mild Cognitive Impairment (MCI) | Subjective Memory Complainers (SMC) | Cognitively Normal (CN) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 5 | 11 | 44 | 25 | 85 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Alzheimer's Disease (AD) | Mild Cognitive Impairment (MCI) | Subjective Memory Complainers (SMC) | Cognitively Normal (CN) | Total |
|---|---|---|---|---|---|
| Australia | 5 | 11 | 45 | 25 | 86 |
| Mini Mental Status Exam (MMSE)(units on a scale) | Alzheimer's Disease (AD) | Mild Cognitive Impairment (MCI) | Subjective Memory Complainers (SMC) | Cognitively Normal (CN) | Total |
|---|---|---|---|---|---|
| Mean | 22.6 ± 3.21 | 25.5 ± 2.84 | 28 ± 1.66 | 28.6 ± 0.99 | 27.5 ± 2.35 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2014 to primary completion in Feb 2018, 40 months.
Results were first posted in Sep 2020, 2 years 7 months after primary completion.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 40 months is above that.
Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flortaucipir